Xeris stockholders approve all proposals; ESPP shares increased by 6.64M

Xeris Biopharma Holdings, Inc.

Third director nominees elected: Edick, Fairley, Persky (58.5M, 58.5M, 47.4M for).
Ernst & Young ratified as auditor for FY2024 (99.5M for).
Advisory vote on executive compensation approved (57.8M for); frequency set at 1 year.
ESPP amendment approved: evergreen provision removed; shares increased by 6,636,632 to 8,854,709.
Broker non-votes on director election and advisory items: ~36.2M shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.